1 赵冰,周琳,刘静,等.促性腺激素释放激素激动剂对卵巢恶性肿瘤患者化疗中生育能力保护作用的研究.中国计划生育和妇产科,2018,10:10-13. 2 Zhang Y,Ji Y,Li J,et al.Sequential versus simultaneous use of chemotherapy and gonadotropin-releasing hormone agonist (GnRHa) among estrogen receptor (ER)-positive premenopausal breast cancer patients:effects on ovarian function,disease-free survival,and overall survival.Breast Cancer Res Treat.2018,168:679-686. 3 李家莹,陈美伶.乳癌妇女化疗引起闭经之现象及其更年期症状表现.护理杂志,2016,63:19 - 26. 4 周林燕,张清学.化疗对卵巢储备功能的影响及相关防治的研究进展.国际生殖健康计划生育杂志,2016,35:493-497. 5 张艳利,薛国军,杨光伦.GnRHa对年轻乳腺癌化疗患者卵巢功能的保护作用.中国普外基础与临床杂志,2018,25:379-383. 6 Moore HC,Unger JM,Phillips KA,et al.Goserelin for ovarian protection during breast-cancer adjuvant chemotherapy.N Engl J Med.2015,372:923-932. 7 Lambertini M,Boni L,Michelotti A,et al.Ovarian suppression with triptorelin during adjuvant breast cancer chemotherapy and long-term ovarian function,pregnancies,and disease-free survival:a randomized clinical trial.Jama,2015,314:2632-2640. 8 Munhoz RR,Pereira AAL,Sasse AD,et al.Gonadotropin-releasing hormone agonists for ovarian function preservation in premenopausal women undergoing chemotherapy for early-stage breast cancer:a systematic review and meta-analysis.Jama Oncol,2016,2:65-73. 9 Bai F,Lu Y,Wu K,et al.Protecting effects of gonadotropin-releasing hormone agonist on chemotherapy-induced ovarian damage in premenopausal breast cancer patients:a systematic review and meta-analysis.Breast Care,2017,12:48-52. 10 Leonard RCF,Adamson DJA,Bertelli G,et al.GnRH agonist for protection against ovarian toxicity during chemotherapy for early breast cancer:the Anglo Celtic Group OPTION trial.Ann Oncol.2017,28:1811-1816. 11 肖苗苗,刘磊,易呈浩,等.促性腺激素释放激素类似物对绝经前乳腺癌化疗患者卵巢功能保护的疗效分析:一项Meta分析.肿瘤,2019,39:40-49. 12 Coates AS,Winer EP,Goldhirsch A,et al.Tailoring therapies-improving the management of early breast cancer:St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015. Ann Oncol.2015,26:1533-1546. 13 Demeestere I,Brice P,Peccatori FA,et al.No evidence for the benefit of gonadotropin-releasing hormone agonist in preserving ovarian function and fertility in lymphoma survivors treated with chemotherapy:final long-term report of a prospective randomized trial.J Clin Oncol.2016,34:2568-2574. 14 Senra JC,Roque M,Mct T,et al.Gonadotropin-releasing hormone agonists for ovarian protection during cancer chemotherapy:systematic review and meta-analysis.Ultrasound Obstet Gynecol,2017,51:77-86. 15 Trapp E,Steidl J,Rack B,et al.Anti-Müllerian hormone (AMH) levels in premenopausal breast cancer patients treated with taxane-based adjuvant chemotherapy - A translational research project of the SUCCESS A study.Breast.2017,35:130-135. 16 Khan HL,Bhatti S,Suhail S,et al.Antral follicle count (AFC) and serum anti-Müllerian hormone (AMH) are the predictors of natural fecundability have similar trends irrespective of fertility status and menstrual characteristics among fertile and infertile women below the age of 40 years.Reprod Biol Endocrinol.2019,17:20. 17 唐移忠,许秀玲,闫冬梅.血清基础抗苗勒管激素和抑制素B与卵巢储备功能的关系及其临床价值分析.中国医药科学,2018,8:224-226.